SG11201810525XA - Anti-gitr antibodies and uses thereof - Google Patents

Anti-gitr antibodies and uses thereof

Info

Publication number
SG11201810525XA
SG11201810525XA SG11201810525XA SG11201810525XA SG11201810525XA SG 11201810525X A SG11201810525X A SG 11201810525XA SG 11201810525X A SG11201810525X A SG 11201810525XA SG 11201810525X A SG11201810525X A SG 11201810525XA SG 11201810525X A SG11201810525X A SG 11201810525XA
Authority
SG
Singapore
Prior art keywords
international
new york
saw mill
river road
tarrytown
Prior art date
Application number
SG11201810525XA
Other languages
English (en)
Inventor
Frank Delfino
Dimitris Skokos
Bei Wang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201810525XA publication Critical patent/SG11201810525XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201810525XA 2016-06-10 2017-06-09 Anti-gitr antibodies and uses thereof SG11201810525XA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662348353P 2016-06-10 2016-06-10
US201662432023P 2016-12-09 2016-12-09
US201762500312P 2017-05-02 2017-05-02
PCT/US2017/036818 WO2017214548A1 (fr) 2016-06-10 2017-06-09 Anticorps anti-gitr et leurs utilisations

Publications (1)

Publication Number Publication Date
SG11201810525XA true SG11201810525XA (en) 2018-12-28

Family

ID=59078260

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810525XA SG11201810525XA (en) 2016-06-10 2017-06-09 Anti-gitr antibodies and uses thereof

Country Status (19)

Country Link
US (3) US10738126B2 (fr)
EP (2) EP3468999B1 (fr)
JP (2) JP7162535B2 (fr)
KR (1) KR102495601B1 (fr)
CN (1) CN109563170B (fr)
AU (1) AU2017278193B9 (fr)
BR (1) BR112018075434A2 (fr)
CA (1) CA3027121A1 (fr)
CL (1) CL2018003515A1 (fr)
CO (1) CO2018013298A2 (fr)
IL (1) IL263273A (fr)
MA (1) MA45233A (fr)
MX (2) MX2018015350A (fr)
MY (1) MY200162A (fr)
PH (1) PH12018502502A1 (fr)
SG (1) SG11201810525XA (fr)
UA (1) UA128687C2 (fr)
WO (1) WO2017214548A1 (fr)
ZA (1) ZA201807920B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
UA128687C2 (uk) 2016-06-10 2024-10-02 Редженерон Фармасьютікалс, Інк. Антитіло до gitr
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
WO2018107178A1 (fr) 2016-12-09 2018-06-14 Regeneron Pharmaceuticals, Inc. Systèmes et procédés de séquençage de récepteurs de cellules t et leurs utilisations
CR20200465A (es) * 2018-03-13 2020-11-17 Tust Therapeutics Ltd Agentes anticuerpos anti-cd25
AU2020223205A1 (en) 2019-02-12 2021-08-05 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
EP4085074A4 (fr) * 2020-01-02 2024-05-15 Nanjing GenScript Biotech Co., Ltd. Anticorps anti-gitr et leurs utilisations
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US11787867B2 (en) 2020-03-06 2023-10-17 Regeneron Pharmaceuticals, Inc. Anti-GITR antibodies and uses thereof
CN116761622A (zh) * 2021-01-08 2023-09-15 苏州丁孚靶点生物技术有限公司 药物产品及其用途
TW202237642A (zh) * 2021-01-08 2022-10-01 美商１０Ｘ基因組學有限公司 對冠狀病毒具有特異性的抗原結合多肽及其用途
KR20240155275A (ko) 2022-03-15 2024-10-28 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 항 글루코코르티코이드 유도 tnfr 관련(gitr) 단백질 항체 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
ES2308787T3 (es) 1996-08-16 2008-12-01 Schering Corporation Antigenos de superficie de celular de mamiferos; reactivos relacionados.
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
DK1032672T3 (da) 1997-11-18 2009-04-27 Genentech Inc DNA19355-polypeptid, en tumornekrosefaktor-homolog
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1462114A1 (fr) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Procédés et moyens pour opprimer les symptomes d'une maladie allergique par inhibition du récepteur du facteur de nécrose tumorale inductible par les glucocorticoides (GRIT ou TNFRSF18)
JP4638876B2 (ja) 2003-05-23 2011-02-23 ワイス Ｇｉｔｒリガンド及びｇｉｔｒリガンド関連分子及び抗体及びその使用
US20060099171A1 (en) 2004-11-05 2006-05-11 Masahide Tone Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
US7812135B2 (en) 2005-03-25 2010-10-12 Tolerrx, Inc. GITR-binding antibodies
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
WO2007084775A2 (fr) 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions et procedes permettant de moduler l’activation d'un lymphocyte t suppresseur
SI2374818T1 (sl) 2006-06-02 2013-03-29 Regeneron Pharmaceuticals, Inc. Visokoafinitetna protitelesa za humani IL-6 receptor
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2009009116A2 (fr) 2007-07-12 2009-01-15 Tolerx, Inc. Thérapies combinées utilisant des molécules de liaison au gitr
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
WO2013039954A1 (fr) 2011-09-14 2013-03-21 Sanofi Anticorps anti-gitr
WO2013051718A1 (fr) 2011-10-07 2013-04-11 国立大学法人三重大学 Récepteur d'antigène chimérique
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
AR097306A1 (es) * 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
EP3148579B1 (fr) 2014-05-28 2020-12-16 Agenus Inc. Anticorps anti-gitr et leurs procédés d'utilisation
EP3151921B1 (fr) * 2014-06-06 2019-08-28 Bristol-Myers Squibb Company Anticorps anti récepteur du facteur de nécrose tumorale induit par glucocorticoïdes (gitr) et leurs utilisations
JP2017531427A (ja) 2014-10-03 2017-10-26 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MX2017005258A (es) 2014-10-31 2017-07-26 Oncomed Pharm Inc Terapia combinada para tratamiento de enfermedad.
UA128687C2 (uk) 2016-06-10 2024-10-02 Редженерон Фармасьютікалс, Інк. Антитіло до gitr

Also Published As

Publication number Publication date
CA3027121A1 (fr) 2017-12-14
EP3468999B1 (fr) 2024-01-10
UA128687C2 (uk) 2024-10-02
MA45233A (fr) 2019-04-17
EP4344748A2 (fr) 2024-04-03
CL2018003515A1 (es) 2019-03-08
EP4344748A3 (fr) 2024-06-12
KR20190020297A (ko) 2019-02-28
MX2022014695A (es) 2022-12-16
CO2018013298A2 (es) 2019-02-19
CN109563170A (zh) 2019-04-02
AU2017278193B9 (en) 2024-02-01
NZ748619A (en) 2024-05-31
US20230042324A1 (en) 2023-02-09
AU2017278193A1 (en) 2018-12-13
CN109563170B (zh) 2023-10-13
BR112018075434A2 (pt) 2019-03-19
US11414494B2 (en) 2022-08-16
AU2017278193B2 (en) 2024-01-18
MY200162A (en) 2023-12-09
KR102495601B1 (ko) 2023-02-06
JP2022159476A (ja) 2022-10-17
PH12018502502A1 (en) 2019-04-08
MX2018015350A (es) 2019-08-26
IL263273A (en) 2018-12-31
JP7162535B2 (ja) 2022-10-28
US20210147565A1 (en) 2021-05-20
JP2019521098A (ja) 2019-07-25
EP3468999A1 (fr) 2019-04-17
US20170355774A1 (en) 2017-12-14
ZA201807920B (en) 2024-01-31
US10738126B2 (en) 2020-08-11
WO2017214548A1 (fr) 2017-12-14

Similar Documents

Publication Publication Date Title
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201909949XA (en) Targeted immunotolerance
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201908391XA (en) Methods for modulating an immune response
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201908420WA (en) Compositions of plinabulin and use thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201906301UA (en) Methods of manufacture of nut flours and formulations for oral immunotherapy